Time filter

Source Type

New Windsor, NY, United States

OXYVITA Inc. | Date: 2013-08-27

Pharmaceutical product, namely, blood substitute for human and veterinary use.

Harrington J.P.,State University of New York at New Paltz | Harrington J.P.,OXYVITA Inc. | Wollocko J.,OXYVITA Inc. | Kostecki E.,OXYVITA Inc. | Wollocko H.,OXYVITA Inc.
Artificial Cells, Blood Substitutes, and Biotechnology | Year: 2011

OxyVita-zero-link polymerized hemoglobin (OxyVita Hb) is a novel generation hemoglobin based oxygen carrier (HBOC). Our focus in this paper is to address the question of "Why is OxyVita Hemoglobin different than the previous generation of HBOCs?" Several critical related topics will be discussed: 1) OxyVita's unique chemistry; 2) the introduction of a viable powder form of OxyVita hemoglobin for dissolution in IV water or other IV fluids; 3) the physiochemical characteristics of OxyVita hemoglobin preparations; 4) the ability to formulate different products based upon specific applications; and 5) the important storage properties essential for use in a wide range of geographical locations. © 2011 Informa Healthcare USA, Inc. Source

Harrington J.P.,State University of New York at New Paltz | Orlig K.,State University of New York at New Paltz | Zito S.L.,State University of New York at New Paltz | Wollocko J.,OXYVITA Inc. | Wollocko H.,OXYVITA Inc.
Artificial Cells, Blood Substitutes, and Biotechnology | Year: 2010

A zero-linked polymeric hemoglobin (OxyVita Hb) has been developed for application as an acellular therapeutic hemoglobin-based-oxygen-carrier (HBOC). For effective and safe oxygen binding, transport and delivery, an HBOC must meet essential molecular requirements related to its structural integrity and redox stability. OxyVita™ is a super polymer possessing an average M.wt. of 17 × 106 Da. Structural integrity was determined by unfolding studies of OxyVita™ in the presence of increasing concentrations of urea. The unfolding midpoints (D1/2) of different preparations of OxyVita™ (solution and powder forms) were compared to Lumbricus Hb (LtHb) and Arenicola Hb (ArHb), natural acellular polymeric hemoglobins, which are serving as models for an effective and safe acellular HBOC. Reduction studies of OxyVita Hb using endogenous reducing agents were also investigated. Results from these studies indicate that: 1) OxyVita Hb exhibits greater resistance to conformational change than either LtHb or ArHb in the reduced (oxyHb) state; and 2) the reduction of met OxyVita Hb to oxyHb occurs slowly in the presence of either ascorbic acid (70% reduction in 560 min.) or β-NADH (40% reduction in 90 min.). These studies provide consistent evidence that OxyVita Hb possesses physiochemical properties that exhibit structural integrity and redox behavior necessary for functioning as an effective and safe HBOC within clinical applications. These results are in agreement with observations made by other investigators as to the reduction in heme-loss of OxyVita Hb, essential for the reversible binding/release of molecular oxygen within the circulatory system. © Informa UK Ltd. Source

Harrington J.P.,OXYVITA Inc. | Wollocko H.,OXYVITA Inc.
Journal of Artificial Organs | Year: 2010

Hemoglobin-based oxygen carriers (HBOC) are being developed to provide the oxygen necessary in clinical situations when whole blood is not available. The safety and effectiveness of each HBOC must be determined before clinical approval. In the past several years animal studies have been conducted with zero-linked polymers to evaluate their effectiveness at delivering oxygen in vivo. Studies have addressed issues associated with interstitial extravasation, cerebral ischemia and blood flow, resuscitation, and coagulation interactions. Several of the investigations reviewed are based on early preparations of zero-linked polymerized bovine hemoglobins (ZL-HbBv), which contained a wide range of high-molecular-weight polymers. Recent studies using the Oxyvita product OxyVita Hb, which contains a more homogenous population (97%) of large-molecular-weight species (∼17 MDa), are also included in this review. © 2010 The Japanese Society for Artificial Organs. Source

Discover hidden collaborations